fat-话题@MedSci - 梅斯（MedSci）

#fat#

32篇内容 | 1591人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2029953, encodeId=dbe2202995330, content=<a href='/topic/show?id=d493e259c9' target=_blank style='color:#2F92EE;'>#fat#</a>, objectTitle=Osteoarthritis Cartilage：研究揭示Visfatin在成骨和成脂MSC分化过程中的作用机制, objectType=article, longId=141015, objectId=426014101589, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=426014101589, replyNumber=0, likeNumber=56, createdTime=2019-04-21, rootId=0, userName=12498bd5m16暂无昵称, userId=198d2500149, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=426014101589, moduleTitle=Osteoarthritis Cartilage：研究揭示Visfatin在成骨和成脂MSC分化过程中的作用机制, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=426014101589)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2029954, encodeId=a7f7202995499, content=<a href='/topic/show?id=d493e259c9' target=_blank style='color:#2F92EE;'>#fat#</a>, objectTitle=Blood：在弥漫性大B细胞淋巴瘤中，B细胞受体介导的NFATc1激活可诱导IL-10/STAT3/PD-L1信号, objectType=article, longId=148786, objectId=bee6148e86b0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bee6148e86b0, replyNumber=0, likeNumber=84, createdTime=2019-05-03, rootId=0, userName=仁医06, userId=55683, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bee6148e86b0, moduleTitle=Blood：在弥漫性大B细胞淋巴瘤中，B细胞受体介导的NFATc1激活可诱导IL-10/STAT3/PD-L1信号, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=bee6148e86b0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2029951, encodeId=d11720299510e, content=<a href='/topic/show?id=d493e259c9' target=_blank style='color:#2F92EE;'>#fat#</a>, objectTitle=BMC Anesthesiol：地氟醚和七氟醚对腹腔镜胆囊切除术患者Nesfatin-1水平的影响：随机对照试验, objectType=article, longId=135491, objectId=489613549174, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=489613549174, replyNumber=0, likeNumber=105, createdTime=2018-07-28, rootId=0, userName=12498bd5m16暂无昵称, userId=198d2500149, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=489613549174, moduleTitle=BMC Anesthesiol：地氟醚和七氟醚对腹腔镜胆囊切除术患者Nesfatin-1水平的影响：随机对照试验, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=489613549174)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2029950, encodeId=73b4202995085, content=<a href='/topic/show?id=d493e259c9' target=_blank style='color:#2F92EE;'>#fat#</a>, objectTitle=对话ABC4大会主席Fatima Cardoso：ABC4共识重大更新以及对中国乳腺癌诊疗的指导价值, objectType=article, longId=119411, objectId=03e611941176, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=03e611941176, replyNumber=0, likeNumber=141, createdTime=2018-08-10, rootId=0, userName=12498bd5m16暂无昵称, userId=198d2500149, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=03e611941176, moduleTitle=对话ABC4大会主席Fatima Cardoso：ABC4共识重大更新以及对中国乳腺癌诊疗的指导价值, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=03e611941176)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2029949, encodeId=5143202994968, content=<a href='/topic/show?id=d493e259c9' target=_blank style='color:#2F92EE;'>#fat#</a>, objectTitle=Lancet Oncol：Ofatumumab维持治疗慢性淋巴细胞白血病效果, objectType=article, longId=56169, objectId=2193561692f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2193561692f, replyNumber=0, likeNumber=0, createdTime=2016-01-30, rootId=0, userName=12498bd5m16暂无昵称, userId=198d2500149, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2193561692f, moduleTitle=Lancet Oncol：Ofatumumab维持治疗慢性淋巴细胞白血病效果, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=2193561692f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2029948, encodeId=d4ff20299482f, content=<a href='/topic/show?id=d493e259c9' target=_blank style='color:#2F92EE;'>#fat#</a>, objectTitle=全球每周口服一次的糖尿病药物Zafatek上市, objectType=article, longId=51339, objectId=6c2d513392c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6c2d513392c, replyNumber=0, likeNumber=88, createdTime=2015-06-23, rootId=0, userName=12498bd5m16暂无昵称, userId=198d2500149, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6c2d513392c, moduleTitle=全球每周口服一次的糖尿病药物Zafatek上市, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=6c2d513392c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2029947, encodeId=c398202994e35, content=<a href='/topic/show?id=d493e259c9' target=_blank style='color:#2F92EE;'>#fat#</a>, objectTitle=糖尿病重磅消息！全球每周一次口服降糖药Zafatek获批！, objectType=article, longId=48663, objectId=57e1486637f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=57e1486637f, replyNumber=0, likeNumber=56, createdTime=2015-08-30, rootId=0, userName=12498bd5m16暂无昵称, userId=198d2500149, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=57e1486637f, moduleTitle=糖尿病重磅消息！全球每周一次口服降糖药Zafatek获批！, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=57e1486637f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2029946, encodeId=edbc202994623, content=<a href='/topic/show?id=d493e259c9' target=_blank style='color:#2F92EE;'>#fat#</a>, objectTitle=勃林格殷格翰抗癌药Giotrif（afatinib）获欧盟批准, objectType=article, longId=25213, objectId=d462252130c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d462252130c, replyNumber=0, likeNumber=70, createdTime=2014-02-19, rootId=0, userName=12498bd5m16暂无昵称, userId=198d2500149, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d462252130c, moduleTitle=勃林格殷格翰抗癌药Giotrif（afatinib）获欧盟批准, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=d462252130c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2029944, encodeId=443e20299443a, content=<a href='/topic/show?id=d493e259c9' target=_blank style='color:#2F92EE;'>#fat#</a>, objectTitle=勃林格殷格翰afatinib获CHMP积极意见, objectType=article, longId=22425, objectId=467622425e9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=467622425e9, replyNumber=0, likeNumber=75, createdTime=2014-07-06, rootId=0, userName=12498bd5m16暂无昵称, userId=198d2500149, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=467622425e9, moduleTitle=勃林格殷格翰afatinib获CHMP积极意见, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=467622425e9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2029943, encodeId=724b202994358, content=<a href='/topic/show?id=d493e259c9' target=_blank style='color:#2F92EE;'>#fat#</a>, objectTitle=FDA：勃林格殷格翰用于NSCLC药物afatinib获FDA批准, objectType=article, longId=21574, objectId=e6e7215e4e2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e6e7215e4e2, replyNumber=0, likeNumber=85, createdTime=2013-12-16, rootId=0, userName=12498bd5m16暂无昵称, userId=198d2500149, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e6e7215e4e2, moduleTitle=FDA：勃林格殷格翰用于NSCLC药物afatinib获FDA批准, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=e6e7215e4e2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2029945, encodeId=31a4202994511, content=<a href='/topic/show?id=d493e259c9' target=_blank style='color:#2F92EE;'>#fat#</a>, objectTitle=FDA：勃林格殷格翰抗癌药afatinib LUX-Lung临床项目硕果累累, objectType=article, longId=22562, objectId=95f622562aa, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=95f622562aa, replyNumber=0, likeNumber=64, createdTime=2014-02-05, rootId=0, userName=12498bd5m16暂无昵称, userId=198d2500149, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=95f622562aa, moduleTitle=FDA：勃林格殷格翰抗癌药afatinib LUX-Lung临床项目硕果累累, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=95f622562aa)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2029942, encodeId=32b72029942c1, content=<a href='/topic/show?id=d493e259c9' target=_blank style='color:#2F92EE;'>#fat#</a>, objectTitle=nesfatin-1: 控制血糖潜在新靶标, objectType=article, longId=3024, objectId=1c933024b6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1c933024b6, replyNumber=0, likeNumber=86, createdTime=2011-12-28, rootId=0, userName=12498bd5m16暂无昵称, userId=198d2500149, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1c933024b6, moduleTitle=nesfatin-1: 控制血糖潜在新靶标, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=1c933024b6)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

fat

2020-05-29

12498bd5m16暂无昵称 (审核中...)

前往app查看评论内容

#fat#

Osteoarthritis Cartilage：研究揭示Visfatin在成骨和成脂MSC分化过程中的作用机制

2019-04-21

仁医06 (审核中...)

前往app查看评论内容

#fat#

Blood：在弥漫性大B细胞淋巴瘤中，B细胞受体介导的NFATc1激活可诱导IL-10/STAT3/PD-L1信号

2019-05-03

12498bd5m16暂无昵称 (审核中...)

前往app查看评论内容

#fat#

BMC Anesthesiol：地氟醚和七氟醚对腹腔镜胆囊切除术患者Nesfatin-1水平的影响：随机对照试验

2018-07-28

12498bd5m16暂无昵称 (审核中...)

前往app查看评论内容

#fat#

对话ABC4大会主席Fatima Cardoso：ABC4共识重大更新以及对中国乳腺癌诊疗的指导价值

2018-08-10

12498bd5m16暂无昵称 (审核中...)

前往app查看评论内容

#fat#

Lancet Oncol：Ofatumumab维持治疗慢性淋巴细胞白血病效果

2016-01-30

12498bd5m16暂无昵称 (审核中...)

前往app查看评论内容

#fat#

全球每周口服一次的糖尿病药物Zafatek上市

2015-06-23

12498bd5m16暂无昵称 (审核中...)

前往app查看评论内容

#fat#

糖尿病重磅消息！全球每周一次口服降糖药Zafatek获批！

2015-08-30

12498bd5m16暂无昵称 (审核中...)

前往app查看评论内容

#fat#

勃林格殷格翰抗癌药Giotrif（afatinib）获欧盟批准

2014-02-19

12498bd5m16暂无昵称 (审核中...)

前往app查看评论内容

#fat#

勃林格殷格翰afatinib获CHMP积极意见

2014-07-06

12498bd5m16暂无昵称 (审核中...)

前往app查看评论内容

#fat#

FDA：勃林格殷格翰用于NSCLC药物afatinib获FDA批准

2013-12-16

12498bd5m16暂无昵称 (审核中...)

前往app查看评论内容

#fat#

FDA：勃林格殷格翰抗癌药afatinib LUX-Lung临床项目硕果累累

2014-02-05

12498bd5m16暂无昵称 (审核中...)

前往app查看评论内容

#fat#

nesfatin-1: 控制血糖潜在新靶标

2011-12-28

科室
- - 订阅+
  - 更多科室
工具
服务